Thanks, Rhett, and good morning, everyone. On Slide 9, we continue to see our overall deposit levels remain stable as we build our presence and gain new clients in our expansion market areas. We ended the quarter with a loan to deposit ratio of 80%, driven by deposit growth of $47 million, which exceeded our quarterly funding needs and further bolstering our liquidity position. However, we did experienced some upward pricing pressure and mix shift, particularly during the first two months of the quarter, as clients reacted to the Fed rate hike and competitor solicitation. Our total deposit costs increased 31 basis points to 2.20% and were 2.28% for the month of September. Despite upward pricing pressure, our strategy of lagging market rate increases and adjusting rates only as needed for competitive purposes has afforded us some buffer relative to peers. Looking ahead, we do expect some additional cost migration as clients right size operating accounts and look to maximize returns on idle cash. However, we believe this will occur at a much more muted pace as most of our price sensitive clients have been addressed. On Slide 10, you'll see that we have updated our principal cash flow schedule to reflect the sale of almost $160 million securities at the end of September. The security sale was comprised primarily of U.S. Treasuries, approximately $100 million of which had maturities in Q1 of 2024 and the remainder of which had a weighted average maturity of 2.6 years. The total weighted average yield of these securities sold was 1.37%. Reinvested at current cash yields, the sale proceeds provide an additional $6.4 million of annual interest income which equates to an earn back just over one year. Aside from the enhanced liquidity benefits, the securities repositioning provides additional earnings momentum as we move into Q4. Further, our current yield on cash affords us the ability to be patient in our redeployment of the sale proceeds, whether it be methodically reinvesting in securities or preferably funding higher-yielding loan production, both of which would accelerate the earn back on this trade. As you'll see on Slide 11, even with the securities repositioned during the quarter, we still have approximately $208 million of securities, primarily comprised of held to maturity treasuries, maturing by year-end 2024. Combined with fixed rate and adjustable rate loans, we have over $460 million in assets maturing or repricing by year-end 2024 with a weighted average yield of 4.08%. While the interest rate environment remains challenging, we are optimistic on future profitability knowing this significant earnings catalyst is on the horizon. Our overall liquidity position on Slide 13, which includes cash and securities, remained unchanged at 22% of total assets. Net interest margin was 2.81%, representing a 12 basis point contraction for the quarter. As discussed earlier, our margin was negatively impacted by increased deposit pricing pressures and mix shift experienced during the quarter. However, we are starting to experience a slowdown in the velocity of money movement and deposit repricing as we move into Q4. In addition, Q3 saw a weighted average cost of new deposit production of 3.59% and new commercial loan originations in the 7.5% to 8% range. These factors, combined with the enhanced yield on repositioned security proceeds, we are projecting margin stabilization into Q4. Lastly, looking ahead at the next few quarters, we expect operating revenue to remain stable in a range of $38 million to $39 million before returning to our previous $42 million plus run rate in the second half of 2024. We have details of our noninterest income and expenses on Slides 15 and 16. Operating noninterest income was in line with Q3 guidance at $7.5 million, primarily driven by ongoing focus to identify and capitalize on those income opportunities as they present themselves. Looking ahead, we anticipate non-interest income to continue to be in the mid $7 million range. Total operating expenses were $28.4 million. The slight escalation was primarily to salary benefit expenses increases for incentives and commissions resulting from better than anticipated production and additional costs relating to the new self-insured health insurance program. While our efficiency ratio was at 74%, which is above our internal target, we recognized that it's primarily a function of the pressures of an abnormal rate environment rather than lack of expense control. Despite this, we continue to be extremely diligent on all expenditures while identifying opportunities to cut or delay expenses. Looking ahead to the fourth quarter, we project noninterest expenses in the 25 -- excuse me, $28.5 million to $29 million range and salary and benefit expenses in the range of $16.5 million to $17 million. And finishing off on Slide 17. We had minimal change to our capital ratios from the prior quarter, even with the loss associated with the securities repositioning. We remain in a strong, well-capitalized position and, most importantly, continue to execute on our primary mission to grow and defend tangible book value. With that said, I'll turn it back over to Billy.